Jasper Therapeutics (JSPR)
NASDAQ:JSPR
Top Page
Jasper Therapeutics
(NASDAQ:JSPR)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.69
▲(0.74% Upside)
Action:ReiteratedDate:03/31/26
The score is held down primarily by weak financial performance (no revenue, expanding losses, heavy cash burn, and a sharply reduced equity base), which increases reliance on external funding. Technicals remain bearish due to a strong downtrend, though oversold indicators provide some near-term support. A positive clinical data event improves the outlook, but not enough to outweigh the current financial risk profile.
Positive Factors
Briquilimab clinical efficacy & tolerability
Robust BEACON and open‑label extension outcomes with rapid and durable responses plus favorable safety support a clear dose choice for a planned Phase 2b in H2 2026. This materially derisks development, strengthens future partner/licensing prospects and advances potential market differentiation long term.
Negative Factors
No revenue & heavy cash burn
Sustained, large negative operating and free cash flow with no product revenue forces repeated external funding or partnerships. This structural cash gap increases dilution risk, constrains multi‑year R&D planning and makes survival dependent on successful financing or milestone monetization rather than internal cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Briquilimab clinical efficacy & tolerability
Robust BEACON and open‑label extension outcomes with rapid and durable responses plus favorable safety support a clear dose choice for a planned Phase 2b in H2 2026. This materially derisks development, strengthens future partner/licensing prospects and advances potential market differentiation long term.
Read all positive factors
Jasper Therapeutics (JSPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.16M
Dividend YieldN/A
Average Volume (3M)399.98K
Price to Earnings (P/E)―
Beta (1Y)2.22
Revenue GrowthN/A
EPS Growth-24.38%
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding27,996,819
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.20
Forecast
1Y Price Target
$9.90Price Target Upside1355.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.86
Revenue Forecast (FY)N/A
Jasper Therapeutics Business Overview & Revenue Model
Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell...
How the Company Makes Money
null...
Jasper Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -82.83M | -74.87M | -67.75M | -50.22M | -36.46M |
| Net Income | -75.80M | -71.27M | -64.47M | -37.69M | -30.64M |
Balance Sheet | |||||
| Total Assets | 35.78M | 79.90M | 94.89M | 48.36M | 93.65M |
| Cash, Cash Equivalents and Short-Term Investments | 28.69M | 71.64M | 86.89M | 38.25M | 84.70M |
| Total Debt | 1.24M | 1.81M | 2.79M | 3.65M | 2.88M |
| Total Liabilities | 31.63M | 18.23M | 16.45M | 12.37M | 24.14M |
| Stockholders Equity | 4.15M | 61.67M | 78.44M | 35.99M | 69.52M |
Cash Flow | |||||
| Free Cash Flow | -77.17M | -63.15M | -52.33M | -46.43M | -36.11M |
| Operating Cash Flow | -77.16M | -62.60M | -52.07M | -45.86M | -33.68M |
| Investing Cash Flow | 5.00K | -532.00K | -267.00K | -576.00K | -2.43M |
| Financing Cash Flow | 34.21M | 47.88M | 100.97M | 55.00K | 100.97M |
Jasper Therapeutics Technical Analysis
Negative
0.68
Price Trends
1.27
Negative
1.50
Negative
2.26
Negative
Market Momentum
-0.16
Positive
16.91
Positive
2.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JSPR, the sentiment is Negative. The current price of 0.68 is below the 20-day moving average (MA) of 1.11, below the 50-day MA of 1.27, and below the 200-day MA of 2.26, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 16.91 is Positive, neither overbought nor oversold. The STOCH value of 2.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JSPR.
Jasper Therapeutics Risk Analysis
Jasper Therapeutics disclosed 84 risk factors in its most recent earnings report. Jasper Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jasper Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $180.18M | -1.26 | -60.22% | ― | -100.00% | -17.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $19.16M | -0.46 | -191.12% | ― | ― | -24.38% | |
49 Neutral | $70.31M | -1.80 | 26.10% | ― | ― | ― | |
46 Neutral | $132.16M | -6.26 | -236.85% | ― | -8.64% | 85.68% | |
45 Neutral | $66.22M | -0.50 | -82.96% | ― | ― | 25.89% | |
43 Neutral | $36.54M | -1.93 | -226.10% | ― | ― | 48.68% |
* Healthcare Sector Average
JSPR
Jasper Therapeutics
0.68
-2.79
-80.29%
CVM
Cel-Sci
4.32
-1.42
-24.73%
BYSI
Beyondspring
1.71
0.56
48.70%
CBUS
Cibus
1.91
0.34
21.66%
ACET
Adicet Bio
6.90
-2.70
-28.12%
ARTV
Artiva Biotherapeutics, Inc.
7.29
5.37
279.69%
Jasper Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria
Positive
Jan 8, 2026
On January 8, 2026, Jasper Therapeutics reported positive updated clinical results for briquilimab in chronic urticaria, with new Phase 1b/2a BEACON data in adults with CSU and longer-term outcomes from an open-label extension study in CSU and CIn...
Business Operations and StrategyExecutive/Board Changes
Jasper Therapeutics announces leadership transition and briquilimab update
Neutral
Jan 7, 2026
On January 2, 2026, Jasper Therapeutics’ board decided that Chief Executive Officer and President Ron Martell would step down effective January 5, 2026, a termination without cause under his contract that entitles him to 18 months of salary ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.